New US approval for Takeda’s Alunbrig
admin 26th May 2020 Uncategorised 0The move is based on data showing Alunbrig’s superiority over crizotinib as first-line treatment of metastatic ALK+ NSCLC
More: New US approval for Takeda’s Alunbrig
Source: News